Targets › IL15RA
3 programs from 3 companies in 27 trials: 15 Phase 2, 11 Phase 1, 1 Phase 3; Oncology, Infectious disease; next expected readout Dec 2026.
High-affinity receptor for interleukin-15. Can signal both in cis and trans where IL15R from one subset of cells presents IL15 to neighboring IL2RG-expressing cells (By similarity). (UniProt, Q13261)
Open in Phaseline: the race on IL15RA, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| ImmunityBio | Nogapendekin Alfa Inbakicept (N803) Interleukin-15 receptor agonist | IL2RG, IL2RB, IL15RA | Phase 3 | NSCLC Stage IV; Long COVID; Platinum-resistant Ovarian Cancer; Relapsed B-Cell Non Hodgkin Lymphoma … | Mar 2027 |
| Suzhou Forlong Biotechnology | FL115 IL-15 agonist (IL-15[N72D]/IL-15Rα-sFc fusion protein) | IL15, IL15RA | Phase 1 | Locally Advanced/Metastatic Solid Tumors; Advanced Solid Tumors; Non-muscle Invasive Bladder Cancer (NMIBC) | Dec 2026 |
| National Cancer Institute (NCI) | Recombinant Human Interleukin-15 (rhIL-15) Interleukin-15 receptor agonist | IL2RG, IL2RB, IL15RA | Phase 1 | Neuroblastoma | Jun 2028 |
Long COVID (2) NSCLC Stage IV (1) Platinum-resistant Ovarian Cancer (1) Relapsed B-Cell Non Hodgkin Lymphoma (1) Pancreatic Cancer (1) Bladder Cancer (1) Non-Small Cell Lung Cancer (1) Glioblastoma (1) Non Hodgkin's Lymphoma Refractory/Relapsed (1) Metastatic Solid Tumor (1) Non-muscle Invasive Bladder Cancer (1) HIV/AIDS (1)
mixed (2), small molecule (1)
ImmunityBio (1) National Cancer Institute (NCI) (1) Suzhou Forlong Biotechnology (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.